Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)

NCT03954327 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.

NCT NCT03954327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03954327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)
Lead sponsor
University of Alberta
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2021
Completion date
January 1, 2024
Enrollment
37 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis